Effects of calcitriol on bone mineral density in patients treated with esomeprazole. (October 2014)

• Record Type: Journal Article
• Authors: Huang, Congwu; Cen, Chuan; Ding, Xin; Zhang, Haiyong; Wu, Lingfei
• Is Part Of: Pharmaceutical biology. Volume 52:Number 10(2014:Oct.)
• Page Start: 1341
• Page End: 1344
• Publication Date: 2014-10
• Subjects: Pharmacognosy -- Periodicals; Materia medica, Vegetable -- Periodicals; 615.321
• DOI: 10.3109/13880209.2014.892141
• Languages: English
• ISSNs: 1388-0209

Abstract

<abstract> <title>Abstract</title> <p> <italic>Context</italic>: Proton pump inhibitor (PPI) increases the risk of decrease in bone mineral density (BMD). However, whether calcitrol improves this situation is unknown.</p> <p> <italic>Objective</italic>: The current study investigates the effects of calcitriol on BMD in patients with esomeprazole therapy.</p> <p> <italic>Materials and methods</italic>: Three hundred and eighty-six participants with gastrointestinal ulcerations were enrolled and randomly assigned into controlled and supplemented groups. Participants in the controlled group were prescribed esomeprazole (20 mg/qd), while the supplemented group was prescribed esomeprazole (20 mg/qd) and calcitriol (2.5 μg/qd). BMD, serum levels of calcium, carboxy-terminal collagen crosslinks (CTX), and alkaline-phosphatase (ALP) were assessed.</p> <p> <italic>Results</italic>: (1) No significant between-group difference of age, gender, smoking, previous glucocorticoid use and hemoglobin level was found; (2) after 10.6 ± 0.8 d of PPI therapy, BMD <italic>T</italic> score in the controlled group was slightly increased compared with initial (−1.25 ± 0.08 versus −1.28 ± 0.06, <italic>p</italic> = 0.084), while there was no change in the supplemented group (−1.25 ± 0.05 versus −1.26 ± 0.03, <italic>p</italic> = 0.308); (3) during study termination, calcium level in the supplemented group was slightly higher than the controlled group (2.05 ± 0.03 mmol/L versus 2.01 ± 0.05 mmol/L, <italic>p</italic> = 0.073), while no significant differences of CTX (366.57 ± 43.71 pg/mL versus 373.15 ± 50.23 pg/mL, <italic>p</italic> = 0.036) and ALP were found among these two groups (50.47 ± 9.32 U/L versus 52.23 ± 10.45 U/L, <italic>p</italic> = 0.075).</p> <p> <italic>Conclusion</italic>: Patients with gastrointestinal ulcerations with esomeprazole therapy, calcitriol supplement showed no efficacy on BMD changes.</p> </abstract>